Ipsen SA’s plans to grow its rare disease activities have been set back by its decision to withdraw the US marketing application for palovarotene, which is being developed for the treatment of the ultra-rare bone disorder, fibrodysplasia ossificans progressive (FOP).
The condition is associated with heterotrophic ossification, the formation of new bone in muscles, tendons and soft tissue, that progresses...